Arcus Biosciences nears key catalysts with late-stage assets & upcoming Phase 3 data. Discover potential upside & why it's ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for ...

A combination of lisocabtagene maraleucel (liso-cel, Breyanzi) plus ibrutinib (Imbruvica) demonstrated a trend for better ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

BioNTech stock was rising after the drugmaker reported better-than-expected results early Monday. The company’s ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst ...